Published in Neurosci Lett on March 20, 2003
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage (2009) 1.63
Can MRI screen for CSF biomarkers in neurodegenerative disease? Neurology (2012) 1.52
Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol (2010) 1.32
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology (2009) 1.10
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol (2015) 0.94
Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther (2010) 0.88
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci (2008) 0.86
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol (2016) 0.84
Insulin increases central apolipoprotein E levels as revealed by an improved technique for collection of cerebrospinal fluid from rats. J Neurosci Methods (2012) 0.84
Central nervous system drug development: an integrative biomarker approach toward individualized medicine. NeuroRx (2005) 0.83
Biological markers and Alzheimer disease: a canadian perspective. Int J Alzheimers Dis (2010) 0.82
Morphological Factor Estimation via High-Dimensional Reduction: Prediction of MCI Conversion to Probable AD. Int J Alzheimers Dis (2011) 0.81
Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Dis Assoc Disord (2012) 0.81
Emerging biomarkers in cognition. Clin Geriatr Med (2013) 0.76
Applying new research criteria for diagnosis of early Alzheimer's disease: sex and intelligence matter. Int J Alzheimers Dis (2009) 0.75
Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. Dement Geriatr Cogn Dis Extra (2017) 0.75
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med (2003) 4.20
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry (2006) 2.39
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord (2007) 2.15
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord (2003) 1.77
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 1.76
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet (2002) 1.73
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res (2003) 1.70
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol (2013) 1.60
Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis (2011) 1.58
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. Am J Ophthalmol (2007) 1.56
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging (2002) 1.56
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis (2007) 1.54
Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg (2012) 1.53
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
A novel pathway for amyloid precursor protein processing. Neurobiol Aging (2009) 1.52
Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res (2007) 1.51
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 1.50
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 1.48
Neurochemical aftermath of amateur boxing. Arch Neurol (2006) 1.47
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol (2013) 1.43
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry (2012) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol (2007) 1.36
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain (2015) 1.36
Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport (2002) 1.35
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol (2010) 1.35
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol (2012) 1.33
TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease. Neurodegener Dis (2005) 1.33
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation (2012) 1.31
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One (2009) 1.30
Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett (2003) 1.29
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res (2006) 1.27
Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc Natl Acad Sci U S A (2011) 1.27
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 1.26
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg (2005) 1.25
CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One (2012) 1.25
Plasma Abeta in Alzheimer's disease--up or down? Lancet Neurol (2006) 1.24
Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int (2006) 1.24
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res (2010) 1.22
Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging (2007) 1.21
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain (2008) 1.20
Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord (2003) 1.20
Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology (2013) 1.20
Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol (2009) 1.19
The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry (2007) 1.18
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther (2010) 1.17
Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J Neurosurg (2009) 1.17
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol (2005) 1.16
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15
Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener (2010) 1.15
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol (2005) 1.14
Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat (2003) 1.14